Concord Drugs Ltd — Others, 22-07-2025: AGM/EGM

Concord Drugs has issued a corrigendum to its Extra-Ordinary General Meeting (EGM) notice, clarifying details of proposed preferential allotments. For the share issue, the company will raise ₹11.53 Cr, allocating 37.5% each to strengthen working capital and upgrade manufacturing facilities for cGMP compliance, with 25% for general corporate purposes. Similarly, for the warrant issue totaling ₹7.35 Cr, funds are proportionally earmarked for working capital, facility upgrades, and general corporate needs. These funds are vital for operational efficiency, regulatory adherence, and future business expansion, impacting shareholder value through improved operations.